D842V

/D842V

Blueprint Medicines Presents Preclinical Data on BLU-285

Blueprint Medicines presented new preclinical data on its drug candidate, BLU-285, and its potential value in  treatment-resistant GIST and on novel cancer drug targets at the AACR (American Association for Cancer Research) Annual Meeting in [...]

By | 2015-04-23T15:54:09+00:00 April 24th, 2015|D842V, News, Research|

D842V Gets Its Moment in the Spotlight

The Gleevec for GIST story continues to remain one of the most successful stories in oncology. What could be better than a drug that works in 85 percent of patients? As great as this story is, there is room for improvement. Half of the patients on Gleevec for metastatic disease will progress in the first two years and 15 percent of patients are resistant to Gleevec right away or within the first six months of treatment. AROG Pharmaceuticals may have an option for a few of those patients.

By | 2018-06-12T11:11:01+00:00 February 1st, 2011|D842V, News, Patient Registry|

References – PDGFRA and D842V

1. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR: Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clin [...]

By | 2014-09-03T13:23:03+00:00 December 20th, 2007|D842V, Mutations, Research|

KIT and PDGFRA Mutations in GIST: A to Z

This is part one of a two-part series on “KIT and PDGFRA kinase mutations in GIST: from A to Z”. In this newsletter, Dr. Heinrich will provide a background on the role of kinase mutations in GIST, focusing largely on the biological and clinical implications of these mutations. In part two (which will be featured in the July 2007 edition of the newsletter, following the special “Five-year anniversary” edition),

Recent Posts

Upcoming Events

  1. Sarcoma & GIST: Education Symposium

    September 29 @ 9:00 AM - 2:45 PM
  2. Michigan GDOL 2018

    Michigan GDOL 2018

    October 27 @ 8:00 AM - 3:00 PM
  3. NTFC

    Night to Fight Cancer

    November 7 @ 6:00 PM - 11:00 PM